Laboratory Summary Report: 2016

Winter Quarter

1. Our Gen31 experiment assays the transgenic Tau Alzheimer’s Disease (AD) flies and our “B” flies with MX100a, memantine (Namenda), and combinations of the two therapies.
2. Memantine (Namenda), is one of only a few “first line” therapies used to treat AD. Genescient made the decision to test memantine using our fly model to validate the model and verify our results to date.
3. We observed that memantine did indeed reduce symptoms in our transgenic Tau flies, thus helping to validate our platform for testing of AD treatments.
4. We saw the most positive results with the co-therapy of MX100a and memantine, suggesting a possible synergistic effect, and a possible avenue for us to explore potential collaborations.
5. Genescient enlists te help of Bob Cruise, Ph.D., to help with our analysis of the human pilot data.
6. We find that Memex seemed to help people with the ApoE4 genotype associated with the onset of AD.

Spring Quarter

1. During our continued analysis of the human pilot data, we compare our data to a study titled “Age and Rate of Cognitive Decline in Alzheimer Disease” by Charles Bernick, et. al., that analyzed 471 AD patients “mild to moderate AD assigned to the placebo arm of 3 clinical trials.”
2. Our patient trajectories are positive compared to the placebos in the Bernick paper, suggesting that MX100a has a positive effect on AD patients.

Fall and Winter Quarter

1. The MX100a patient registry has continued to grow to over 200 participants.
2. The patients appear to be stabilizing, and Dr. Shankle continues to recommend MX100a to all of his patients.
3. At this time, it’s the further fortified MX100a+ that the patients are taking.
4. Genescient begins work on a paper to report our results with the transgenic AD flies and subsequent human pilot study.